CD274 and non-small cell lung carcinoma: Bensch F. et al. presented the initial results from a first-in-human study to assess the feasibility of imaging with zirconium-89-labeled atezolizumab and tested its potential to predict a clinical response to PD-L1 blockade in NSCLC [42].